- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- amphetamine extended-release oral suspension, 2.5 mg/mL, Placebo extended-release oral suspension
- Drug
- Lead sponsor
- Tris Pharma, Inc.
- Industry
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Las Vegas, Nevada
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 457–480
of 33,028
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Parkinson Disease
- Interventions
- Terazosin 5 MG, Placebo oral capsule
- Drug
- Lead sponsor
- Jordan Schultz
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- HIV Infections
- Interventions
- Nelfinavir mesylate
- Drug
- Lead sponsor
- Agouron Pharmaceuticals
- Industry
- Eligibility
- 13 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Los Angeles, California • New Orleans, Louisiana + 1 more
- Conditions
- Schizophrenia, Schizoaffective Disorder
- Interventions
- Probiotic Supplement, Identical-appearing Placebo
- Dietary Supplement
- Lead sponsor
- Sheppard Pratt Health System
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Towson, Maryland
- Conditions
- CBD
- Interventions
- CBD, Placebo
- Drug
- Lead sponsor
- Hartford Hospital
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Hartford, Connecticut
- Conditions
- CDI
- Interventions
- Vancomycin 125 MG po BID
- Drug
- Lead sponsor
- Creighton University
- Other
- Eligibility
- 65 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection
- Interventions
- Losartan, Placebo
- Drug · Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 205 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 13
- States / cities
- Gainesville, Florida • Jacksonville, Florida • Atlanta, Georgia + 8 more
- Conditions
- Amputation Stumps, Neuroma
- Interventions
- Bupivacaine, Placebo
- Drug
- Lead sponsor
- Shirley Ryan AbilityLab
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Alzheimer Disease
- Interventions
- atomoxetine hydrochloride, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 3
- States / cities
- Sherman Oaks, California • Rochester, New York • Wichita Falls, Texas
- Conditions
- Parkinsons Disease
- Interventions
- Mirabegron, Placebo
- Drug
- Lead sponsor
- Daniel Burdick, MD
- Individual
- Eligibility
- 30 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Kirkland, Washington
- Conditions
- Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant, Prevention of CDI in Adult Patients Being Treated With IV Beta-lactam Antibiotics
- Interventions
- SYN-004, Ribaxamase or Placebo
- Biological
- Lead sponsor
- Theriva Biologics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2030
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Saxagliptin + Metformin, Placebo + Metformin, Pioglitazone
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 77 Years
- Enrollment
- 1,462 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 95
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Calera, Alabama + 92 more
- Conditions
- Autism Spectrum Disorder
- Interventions
- JNJ-42165279, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 13 Years to 35 Years
- Enrollment
- 78 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 9
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Orange, California + 6 more
- Conditions
- Glaucoma Open-Angle Primary, Ocular Hypertension
- Interventions
- H-1337 0.6%, H-1337 1.0%, H-1337 Placebo, Timolol 0.5%
- Drug
- Lead sponsor
- D. Western Therapeutics Institute, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 201 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 9
- States / cities
- Glendale, California • Colorado Springs, Colorado • Lakeland, Florida + 6 more
- Conditions
- Heart Failure
- Interventions
- Spironolactone
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy
- Interventions
- Coffee, Decaffeinated coffee
- Dietary Supplement
- Lead sponsor
- Temple University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Placebo, RO7204239
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Orange, California • Aurora, Colorado • Fairway, Kansas + 1 more
- Conditions
- Alcohol Drinking
- Interventions
- Guanfacine 3mg/day, Guanfacine 1.5mg/day, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 21 Years to 65 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2020
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Prostate Adenocarcinoma
- Interventions
- Fesoterodine, Placebo oral tablet
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 30 Years to 90 Years · Male only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Microbial Colonization, Extreme Prematurity, Early-Onset Neonatal Sepsis, Late-Onset Neonatal Sepsis, Necrotizing Enterocolitis of Newborn, Death; Neonatal
- Interventions
- Ampicillin, Gentamycin, Normal saline
- Drug
- Lead sponsor
- Michael Morowitz
- Other
- Eligibility
- Up to 4 Hours
- Enrollment
- 359 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 14
- States / cities
- Mobile, Alabama • San Diego, California • New Haven, Connecticut + 10 more
- Conditions
- Stroke, Acute
- Interventions
- Valsartan
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Fragile X Syndrome
- Interventions
- AFQ056, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Sacramento, California • Decatur, Georgia + 9 more
- Conditions
- ADPKD
- Interventions
- Spironolactone, Sugar pill
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 20 Years to 55 Years
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- COVID, Infectious Disease
- Interventions
- High-Titer COVID-19 Convalescent Plasma (HT-CCP), Standard Plasma (FFP)
- Biological
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 12 Months and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts